Sildenafil

Generic Name: Sildenafil

Brand Names: Liqrev, Revatio, Viagra, Vizarsin, Sildenafil Actavis, Sildenafil ratiopharm, Granpidam, Sildenafil Teva, Mysildecard

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₃₀N_₆O_₄S

CAS Number: 139755-83-2

Unique Ingredient Identifier: 3M7OB98Y7H

Background: In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) . The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently faci...

Indication: Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications:

(1) the treatment of erectile dysfunction ; and

(2) treatment of pulmonary hypertension, where:
...

Associated Conditions: Erectile Dysfunction, NYHA Functional Class II-III Pulmonary arterial hypertension, Premature Ejaculation, Pulmonary Arterial Hypertension (PAH)

Associated Therapies: -

Clinical Trials

Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy

Phase 4

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Riociguat (Adempas, BAY63-2521)
Drug: Sildenafil
Drug: Tadalafil

First Posted Date: 2016-09-08

Last Posted Date: 2021-02-26

Lead Sponsor: Bayer

Target Recruit Count: 225

Registration Number: NCT02891850

Sildenafil Administration to Treat Neonatal Encephalopathy

Phase 1

Completed

Conditions: Neonatal Encephalopathy

Interventions: Drug: Ora-Blend
Drug: Sildenafil

First Posted Date: 2016-06-24

Last Posted Date: 2022-02-08

Lead Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Target Recruit Count: 28

Registration Number: NCT02812433

Locations: 🇨🇦
Montreal Children's Hospital, Montreal, Quebec, Canada

Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment

Phase 3

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Nintedanib
Drug: Placebo
Drug: Sildenafil

First Posted Date: 2016-06-16

Last Posted Date: 2019-01-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 274

Registration Number: NCT02802345

Locations: 🇦🇺
Royal Prince Alfred Hospital, Camperdown, Sydney, New South Wales, Australia
🇫🇷
HOP Bichat, Paris, France
🇮🇳
Care Institute Of Medical Sciences, Ahmedabad, India

and more 82 locations

Induction of Migraine Aura With Sildenafil

Early Phase 1

Completed

Conditions: Migraine With Aura

Interventions: Drug: Sildenafil
Drug: Placebo

First Posted Date: 2016-06-10

Last Posted Date: 2021-11-16

Lead Sponsor: Herlev Hospital

Target Recruit Count: 16

Registration Number: NCT02795351

Locations: 🇩🇰
Department of Neurology, Herlev-Gentofte Hospital, Herlev, Denmark

Efficacy of Sildenafil in Preterm Preeclampsia

Phase 2

Withdrawn

Conditions: Preterm Preeclampsia

Interventions: Drug: Sildenafil
Drug: Placebo

First Posted Date: 2016-05-25

Last Posted Date: 2018-03-27

Lead Sponsor: The University of Texas Health Science Center, Houston

Registration Number: NCT02782559

Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema

Phase 4

Recruiting

Conditions: Emphysema

Interventions: Drug: Hypoxia administration study group
Drug: Hyperoxia administration study group
Drug: Sildenafil

First Posted Date: 2016-02-15

Last Posted Date: 2024-03-28

Lead Sponsor: Eric A. Hoffman

Target Recruit Count: 80

Registration Number: NCT02682147

Locations: 🇺🇸
University of Iowa, Iowa City, Iowa, United States

Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: placebo
Drug: sildenafil

First Posted Date: 2015-12-10

Last Posted Date: 2019-07-24

Lead Sponsor: National Jewish Health

Target Recruit Count: 14

Registration Number: NCT02626182

Locations: 🇺🇸
National Jewish Health, Denver, Colorado, United States

Oral Sildenafil and Intravenous Milrinone on Postoperative Pulmonary Hypertension

Phase 1

Completed

Conditions: Pulmonary Hypertension

Interventions: Drug: milrinone
Drug: Sildenafil

First Posted Date: 2015-11-03

Last Posted Date: 2015-11-13

Lead Sponsor: Assiut University

Target Recruit Count: 30

Registration Number: NCT02595541

Sildenafil Activates Browning of White Adipose and Improves Insulin Sensitivity

Phase 4

Conditions: Obesity

Interventions: Drug: placebo
Drug: sildenafil

First Posted Date: 2015-08-14

Last Posted Date: 2016-09-02

Lead Sponsor: Xiang Guang-da

Target Recruit Count: 11

Registration Number: NCT02524184

Locations: 🇨🇳
Wuhan General Hospital, Wuhan, Hubei, China

Phosphodiesterase 5 Inhibitors (PDE5i) (Sildenafil) as Medical Expulsive Therapy in Distal Ureteral Stones

Phase 4

Conditions: Urolithiasis
Ureteral Stone

Interventions: Drug: Sildenafil

First Posted Date: 2015-08-10

Last Posted Date: 2017-07-05

Lead Sponsor: Mansoura University

Target Recruit Count: 100

Registration Number: NCT02519153

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy